Aurobindo Completes the Acquisition of Apotex’ Businesses in Poland, Czech Republic, the Netherlands, Spain and Belgium

Ref: Aurobindo Pharma

Hyderabad, India, 11th February 2019: Aurobindo Pharma Limited (BSE: 524804 and NSE: AUROPHARMA) ("Aurobindo"), a world-leading marketer and manufacturer of generic pharmaceuticals and active pharmaceutical ingredients, today announced that it has closed the acquisition of Apotex’s commercial operations and certain supporting infrastructure in five European countries.

The binding agreement to acquire five of Apotex' European businesses, including infrastructure, personnel, products, certain established trademarks, marketing authorizations and dossier license rights in Poland, the Czech Republic, the Netherlands (including the manufacturing facility in Leiden), Spain and Belgium was announced on 14 July 2018.

This announcement does not constitute a recommendation to shareholders or potential investors.

Jefferies International Limited acted as sole financial advisor and Herbert Smith Freehills LLP acted as legal counsel to Aurobindo. Ernst & Young, India provided financial due diligence services.

About Aurobindo
Aurobindo Pharma Limited (www.aurobindo.com) (NSE: AUROPHARMA, BSE: 524804, Reuters: ARBN.NS, Bloomberg: ARBP:IN), is a world-leading marketer and manufacturer of generic pharmaceuticals and active pharmaceutical ingredients. The company’s robust product portfolio is spread over 7 major therapeutic/product areas encompassing Antibiotics, Anti-Retrovirals, CVS, CNS, Gastroenterologicals, Anti-Allergies and Anti-Diabetics. The US and Europe are Aurobindo’s two most important markets accounting for over 70% of the company’s $ 2.6 billion sales. The company’s new product development activities are driven by an outstanding R&D organization. The company’s manufacturing facilities are approved by the world’s leading regulatory agencies including US FDA, UK MHRA, Japan PMDA, WHO, Health Canada, MCC South Africa, ANVISA Brazil. Aurobindo is headquartered in Hyderabad, India.

Disclaimer
This press release contains statements that may constitute “forward looking statements” including and without limitation, statements relating to product characteristics and uses, sales potential and target dates for product launch, implementation of strategic initiatives, and other statements relating to our future business developments and economic performance. While these forward-looking statements represent our judgment and future expectations concerning the development of our business, a number of risks, uncertainties and other factors could cause actual developments and results to differ materially from our expectations. The company undertakes no obligation to publicly revise any forward-looking statements to reflect future events or circumstances and will not be held liable for any use of this information.